Rapamycin Inhibits the Growth and Metastatic Progression of Non-Small Cell Lung Cancer
- 1 January 2004
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (1), 293-300
- https://doi.org/10.1158/1078-0432.ccr-0629-3
Abstract
Purpose: Lung cancer has a dismal prognosis and comprises 5.5% of post-transplant malignancies. We explored whether rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer (NSCLC). Experimental Design: Murine KLN-205 NSCLC was used as the model tumor in syngeneic DBA/2 mice to explore the effect of rapamycin on tumor growth and metastastic progression. We also examined the effect of rapamycin on cell cycle progression, apoptosis, and proliferation using murine KLN-205 NSCLC cells and human A-549 NSCLC cells as targets. The in vivo and in vitro effects of cyclosporine and those of rapamycin plus cyclosporine were also investigated. Results: Rapamycin but not cyclosporine inhibited tumor growth; s.c. tumor volume was 1290 ± 173 mm3 in untreated DBA/2 mice, 246 ± 80 mm3 in mice treated with rapamycin, and 1203 ± 227 mm3 in mice treated with cyclosporine (P < 0.001). Rapamycin but not cyclosporine prevented the formation of distant metastases; eight of eight untreated mice and four of six mice treated with cyclosporine developed pulmonary metastases whereas only one of six mice treated with rapamycin developed pulmonary metastases (P = 0.003). In vitro, rapamycin induced cell cycle arrest at the G1 checkpoint and blocked proliferation of both KLN-205 and A-549 cells but did not induce apoptosis. Cyclosporine did not prevent cell cycle progression and had a minimal antiproliferative effect on KLN-205 and A-549 cells. Conclusions: The immunosuppressive macrolide rapamycin but not cyclosporine prevents the growth and metastatic progression of NSCLC. A rapamycin-based immunosuppressive regimen may be of value in recipients of allografts.Keywords
This publication has 30 references indexed in Scilit:
- Phospholipase D confers rapamycin resistance in human breast cancer cellsOncogene, 2003
- Rapamycin is an effective inhibitor of human renal cancer metastasis11See Editorial by Sukhatme and Strom, p. 1160.Kidney International, 2003
- Clinical Pharmacokinetics of SirolimusClinical Pharmacokinetics, 2001
- The rapamycin-sensitive signal transduction pathway as a target for cancer therapyOncogene, 2000
- SUPERIORITY OF SIROLIMUS (RAPAMYCIN) OVER CYCLOSPORINE IN AUGMENTING ALLOGRAFT AND XENOGRAFT SURVIVAL IN MICE TREATED WITH ANTILYMPHOCYTE SERUM AND DONOR-SPECIFIC BONE MARROW1Transplantation, 1997
- CARCINOMA OF THE LUNG AFTER HEART TRANSPLANTATIONTransplantation, 1996
- Solid tumors after heart transplantation: Lethality of lung cancerThe Annals of Thoracic Surgery, 1995
- A mammalian protein targeted by G1-arresting rapamycin–receptor complexNature, 1994
- Rapamycin-Induced Inhibition of the 70-Kilodalton S6 Protein KinaseScience, 1992
- Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.The Journal of Antibiotics, 1975